April 27th 2024
Targeted therapies and immunotherapies across the ovarian, endometrial, and cervical cancers landscape play expanded roles, according to Ritu Salani, MD, MBA.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Extending Progression-Free Survival in Ovarian Cancer With Pazopanib
September 25th 2013Andreas du Bois, MD, a professor of gynecologic oncology at Kliniken Essen Mitte in Essen, Germany, discusses a phase III trial exploring the effectiveness of treatment with maintenance pazopanib for patients with advanced ovarian cancer.
Watch
Phase III Study Revives Olaparib as Treatment for Ovarian Cancer
September 5th 2013A phase III clinical program to investigate olaparib as a treatment for patients with BRCA-mutated ovarian cancer marks a step forward in the revived development of an agent that was once left on the sidelines.
Read More
Chemoresponse Assay Demonstrates Utility in Recurrent Ovarian Cancer
August 22nd 2013A study shows that a new chemoresponse assay improves the overall survival and progression-free survival of patients with recurrent ovarian cancer while helping clinicians individualize care for those patients.
Read More
Using the Angiogenesis Inhibitor Pazopanib to Treat Ovarian Cancer
June 2nd 2013Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses a phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Read More